Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

AIDS drug helps to keep HBV at bay during chemotherapy for breast cancer

18.03.2004


Researchers in Hong Kong have discovered a way to help prevent the reactivation of the hepatitis B virus in women who are being treated with chemotherapy for breast cancer.



Dr Winnie Yeo told the 4th European Breast Cancer Conference in Hamburg: "In several developing countries, as many as twelve per cent of breast cancer patients carry the hepatitis B virus. These patients are at risk of developing HBV reactivation during chemotherapy, which is a well-known complication resulting in varying degrees of liver damage that may lead to death."*

Chemotherapy suppresses the immune system and therefore allows the virus to replicate. Once chemotherapy stops, the immune system recovers and attempts to clear the virus and this causes the biochemical flare-up of hepatitis.


However, Dr Yeo has found that the anti-viral drug lamivudine can reduce the risk of HBV reactivation during and after chemotherapy. Lamivudine was initially used for treating HIV infection in AIDS patients and now is used frequently for treating HBV infection.

Dr Yeo, an associate professor in the Department of Clinical Oncology at the Chinese University of Hong Kong, treated 27 HBV-carrying breast cancer patients with lamivudine before, during and up to eight weeks after chemotherapy. She compared the results with a control group of 41 consecutive patients who had had chemotherapy without lamivudine and compared the incidence of HBV reactivation, hepatitis, severe hepatitis and any consequent disruption to the chemotherapeutic regime.

"We found that lamivudine significantly reduced the incidence of HBV reactivation, and that the incidence of hepatitis from all causes was reduced," said Dr Yeo.

Only two patients out of the 27 receiving lamivudine suffered HBV reactivation compared with 17 out of 41 in the control group (seven per cent versus 41 per cent); three patients in the study group suffered from hepatitis and two from severe hepatitis (eleven and seven per cent) compared with 27 patients in the control group who developed hepatitis and six who developed severe hepatitis (66 and 15 per cent). Chemotherapy was disrupted in seven (26 per cent) of the study group and in 21 (51 per cent) of the control group.

Patients in both groups were similar, although more patients were being treated with anthracyclines in the lamivudine group (26 out of 27 patients) than in the control group (23 out of 41 patients).

Dr Yeo said: "These results show very clearly that prophylactic lamivudine significantly reduces the incidence of both HBV reactivation and hepatitis. Therefore I propose that breast cancer patients who are hepatitis B carriers should have anti-viral treatment before the start of chemotherapy."

Emma Mason | EurekAlert!
Further information:
http://www.fecs.be/

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

A Map of the Cell’s Power Station

18.08.2017 | Life Sciences

Engineering team images tiny quasicrystals as they form

18.08.2017 | Physics and Astronomy

Researchers printed graphene-like materials with inkjet

18.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>